<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of uncomplicated non-falciparum malaria in pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of uncomplicated non-falciparum malaria in pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of uncomplicated non-falciparum malaria in pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Type of infection</td> <td class="subtitle1">Trimester</td> <td class="subtitle1">Drug and dose</td> </tr> <tr> <td rowspan="2"><strong>Chloroquine-resistant infection</strong></td> <td>First trimester</td> <td> <p><strong>Artemether-lumefantrine:</strong>* 1 tablet = 20 mg artemether and 120 mg lumefantrine. A three-day treatment schedule with a total of six oral doses is recommended based on weight (25 to 34 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose). The patient should receive the initial dose, followed by the second dose 8 hours later, then 1 dose orally twice daily for the following two days. Take after a full meal or whole milk.</p> <p><strong>or</strong></p> <strong>Other artemisinin combination therapy:</strong> – One of the following: <ul class="decimal_heading"> <li><strong>Dihydroartemisinin-piperaquine:</strong><sup>¶</sup> 1 tablet = 40 mg of dihydroartemisinin and 320 mg of piperaquine phosphate. Dosing for patients 36 to &lt;60 kg consists of 3 tablets orally per day for three days. Dosing for patients 60 to &lt;80 kg consists of 4 tablets per day orally for three days.</li> <li><strong>Artesunate-mefloquine:</strong> 1 tablet = 100 mg artesunate and 220 mg mefloquine hydrochloride per tablet. Dosing for patients ≥30 kg consists of 2 tablets per day orally for three days.</li> <li><strong>Artesunate-amodiaquine:</strong> 1 tablet = 100 mg artesunate and 270 mg amodiaquine. Dosing for patients ≥36 kg consists of 2 tablets per day orally for three days.</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <strong>Quinine sulfate:</strong><sup>Δ</sup> 542 mg base (= 650 mg salt) orally 3 times daily for three or seven days.</td> </tr> <tr> <td>Second or third trimester</td> <td><strong>Artemisinin combination therapy</strong> – One of the following (dosing above): <ul class="decimal_heading"> <li><strong>Artemether-lumefantrine</strong>*</li> <li><strong>Dihydroartemisinin-piperaquine</strong><sup>¶</sup></li> <li><strong>Artesunate-mefloquine</strong></li> <li><strong>Artesunate-amodiaquine</strong></li> </ul> <p class="extra_spacing"><strong>or</strong></p> <strong>Quinine sulfate</strong> (dosing above).</td> </tr> <tr> <td rowspan="2"><strong>Chloroquine-sensitive infection</strong></td> <td>First trimester</td> <td><strong>Chloroquine:</strong> <ul class="decimal_heading"> <li>Dose 1: 600 mg base (= 1000 mg salt) orally</li> <li>Doses 2 to 4 (3 additional doses) at 6, 24, and 48 hours: 300 mg base (= 500 mg salt) orally</li> <li>Total dose: 1500 mg base (= 2500 mg salt)<sup>◊</sup></li> </ul> <p class="extra_spacing"><strong>or</strong></p> <strong>Hydroxychloroquine:</strong> <ul class="decimal_heading"> <li>Dose 1: 620 mg base (= 800 mg salt) orally</li> <li>Doses 2 to 4 (3 additional doses) at 6, 24, and 48 hours: 310 mg base (= 400 mg salt) orally per dose</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <p><strong>Artemether-lumefantrine:</strong>* 1 tablet = 20 mg artemether and 120 mg lumefantrine. A three-day treatment schedule with a total of six oral doses is recommended based on weight (25 to 34 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose). The patient should receive the initial dose, followed by the second dose 8 hours later, then 1 dose orally twice daily for the following two days. Take after a full meal or whole milk.</p> <p><strong>or</strong></p> <strong>Other artemisinin combination therapy</strong> – One of the following (dosing above): <ul class="decimal_heading"> <li>Dihydroartemisinin-piperaquine<sup>¶</sup></li> <li>Artesunate-mefloquine</li> <li>Artesunate-amodiaquine</li> </ul> </td> </tr> <tr> <td>Second or third trimester</td> <td> <p><strong>Chloroquine or hydroxychloroquine:</strong> Dosing as above.</p> <p><strong>or</strong></p> <strong>Artemisinin combination therapy</strong> – One of the following (dosing as above): <ul class="decimal_heading"> <li><strong>Artemether-lumefantrine</strong>*</li> <li><strong>Dihydroartemisinin-piperaquine</strong><sup>¶</sup></li> <li><strong>Artesunate-mefloquine</strong></li> <li><strong>Artesunate-amodiaquine</strong></li> </ul> </td> </tr> <tr> <td><strong>Anti-relapse therapy</strong> (for infections with <em>P. vivax</em> of <em>P. ovale</em>)</td> <td>Refer to separate table</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The dosing regimens listed in this table are generally consistent with the World Health Organization 2015 guidelines (3<sup>rd</sup> edition) for the treatment of malaria and United States Centers for Disease Control and Prevention guidelines for the treatment of uncomplicated malaria in the United States (as revised July 2013) and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class="graphic_footnotes"><p>G6PD: glucose-6-phosphate-dehydrogenase.</p>
<p>* Among the ACTs, artemether-lumefantrine has been associated with the most favorable safety data in pregnancy. Refer to related UpToDate content for further discussion.</p>
<p>¶ Piperaquine component prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine; avoid use in patients with congenital QT prolongation or who are on medications that prolong the QT interval. Dihydroartemisinin-piperaquine may be taken with food but should not be taken with a high-fat meal.</p>
<p>Δ For infections acquired in Southeast Asia, quinine treatment should continue for seven days. For infections acquired in Africa and South America, quinine treatment should continue for three days. In the United States, quinine is encapsulated in a 324 mg (sulfate salt) dose; therefore, for adult dosing, two capsules are sufficient.</p>
◊ The dosing for chloroquine summarized in the table is based on the recommendations of the United States Centers for Disease Control and Prevention. The dosing for chloroquine recommended by the World Health Organization consists of the following: Total dose: 25 mg base/kg, administered as 10 mg base/kg orally on day 1 followed by 10 mg/kg orally on day 2, and 5 mg/kg base on day 3.</div><div class="graphic_reference">Data from:
<ol>
<li>United States Centers for Disease Control and Prevention. Guidelines for Treatment of Malaria in the United States: <a href="https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table.pdf" target="_blank">https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table.pdf</a> (Accessed on September 15, 2022).</li>
<li>WHO Guidelines for malaria, 25 November 2022. Geneva: World Health Organization; 2022 (WHO/UCN/GMP/2022.01 Rev.3). License: CC BY-NC-SA 3.0 IGO. <a href="https://www.who.int/publications/i/item/guidelines-for-malaria" target="_blank">https://www.who.int/publications/i/item/guidelines-for-malaria</a></li>
</ol></div><div id="graphicVersion">Graphic 107719 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
